Stay updated with breaking news from Bioatla Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release - Shareholders Foundation, Inc. - Investigation for Investors in Hywin Holdings Ltd. (NASDAQ: HYW) over potential Wrongdoing announced - published on openPR.com
BioAtla (NASDAQ:BCAB – Free Report) had its target price cut by JMP Securities from $12.00 to $5.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a market outperform rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $7.00 target price on shares of […]
BioAtla (NASDAQ:BCAB – Free Report) had its price target cut by JMP Securities from $12.00 to $5.00 in a report issued on Thursday, Benzinga reports. They currently have a market outperform rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $7.00 price target on shares of BioAtla in a research […]
HC Wainwright reaffirmed their buy rating on shares of BioAtla (NASDAQ:BCAB – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for BioAtla’s Q2 2024 earnings at ($0.51) EPS, Q3 2024 earnings at ($0.48) […]
Biotechnology company BioAtla, Inc. (BCAB) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types.